K. P. Theall

411 total citations
9 papers, 140 citations indexed

About

K. P. Theall is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, K. P. Theall has authored 9 papers receiving a total of 140 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Otorhinolaryngology. Recurrent topics in K. P. Theall's work include Cancer Treatment and Pharmacology (5 papers), Advanced Breast Cancer Therapies (3 papers) and Head and Neck Cancer Studies (2 papers). K. P. Theall is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Advanced Breast Cancer Therapies (3 papers) and Head and Neck Cancer Studies (2 papers). K. P. Theall collaborates with scholars based in United States, Italy and Spain. K. P. Theall's co-authors include T. A. Kennedy, Rochelle Strenger, Mary Anne Fenton, William M. Sikov, Robert D. Legare, Jennifer Gass, Don S. Dizon, Theresa A. Graves, Andrew X. Zhu and Olga Kozyreva and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

K. P. Theall

9 papers receiving 137 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. P. Theall United States	4	95	70	27	23	21	9	140
Yakup Ergün Türkiye	7	122 1.3×	62 0.9×	58 2.1×	24 1.0×	12 0.6×	44	181
A. van de Wouw Netherlands	4	149 1.6×	38 0.5×	67 2.5×	14 0.6×	18 0.9×	8	190
J. G. M. Segalla Brazil	8	80 0.8×	17 0.2×	53 2.0×	40 1.7×	7 0.3×	21	162
Yan-Fang Ye China	7	76 0.8×	28 0.4×	44 1.6×	47 2.0×	11 0.5×	7	167
Govind K Babu India	6	62 0.7×	23 0.3×	63 2.3×	12 0.5×	6 0.3×	13	105
Adeline Cuggia Canada	5	134 1.4×	42 0.6×	47 1.7×	33 1.4×	5 0.2×	5	159
Marie-Paule Sablin France	4	63 0.7×	24 0.3×	45 1.7×	11 0.5×	37 1.8×	4	135
Roger Esteban-Fabró Spain	4	61 0.6×	71 1.0×	46 1.7×	13 0.6×	70 3.3×	8	152
Marla Lipsyc United States	3	107 1.1×	46 0.7×	25 0.9×	30 1.3×	31 1.5×	6	141

Countries citing papers authored by K. P. Theall

Since Specialization

Citations

This map shows the geographic impact of K. P. Theall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. P. Theall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. P. Theall more than expected).

Fields of papers citing papers by K. P. Theall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. P. Theall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. P. Theall. The network helps show where K. P. Theall may publish in the future.

Co-authorship network of co-authors of K. P. Theall

This figure shows the co-authorship network connecting the top 25 collaborators of K. P. Theall. A scholar is included among the top collaborators of K. P. Theall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. P. Theall. K. P. Theall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Ibrahim, Nuhad K., Sung‐Bae Kim, Nancy U. Lin, et al.. (2024). Abstract PO2-05-05: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC). Cancer Research. 84(9_Supplement). PO2–5. 3 indexed citations

Rugo, Hope S., Aditya Bardia, Javier Cortés, et al.. (2024). Abstract PO2-05-04: ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). Cancer Research. 84(9_Supplement). PO2–5. 1 indexed citations

Finn, Richard S., Hope S. Rugo, Karen Gelmon, et al.. (2020). Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis. Cancer Research. 80(4_Supplement). P1–19. 1 indexed citations

Harbeck, Nadia, Massimo Cristofanilli, Jungsil Ro, et al.. (2015). 1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes. European Journal of Cancer. 51. S270–S271. 3 indexed citations

Kozyreva, Olga, Jeffrey W. Clark, Hong Wang, et al.. (2011). A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma. The Oncologist. 16(3). 310–318. 26 indexed citations

Ready, Neal, Ritesh Rathore, Ahmed Nadeem, et al.. (2011). Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 35(1). 6–12. 16 indexed citations

Sikov, William M., Don S. Dizon, Rochelle Strenger, et al.. (2009). Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. Journal of Clinical Oncology. 27(28). 4693–4700. 85 indexed citations

Rathore, Ritesh, Prakash Chougule, H. J. Wanebo, et al.. (2005). Phase II study of induction weekly paclitaxel, ifosfamide, and carboplatin (PIC) followed by chemoradiotherapy (CRT) in locally advanced head and neck squamous cell cancer (HNSCC): A Brown University Oncology Group study (HN-86). Journal of Clinical Oncology. 23(16_suppl). 5556–5556. 2 indexed citations

Theall, K. P., et al.. (2005). Gemcitabine and capecitabine in metastatic breast cancer (MBC): A Brown University Oncology Group (BrUOG) phase II study. Journal of Clinical Oncology. 23(16_suppl). 785–785. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact